Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Micafungin vs Caspofungin in Invasive Candidiasis
NCT00105144Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Sep 2004
- Primary completion
- Apr 2006
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial of micafungin in invasive candidiasis and candidemia (3 arms), sponsored by Astellas Pharma. Primary endpoint: Overall treatment success (clinical and mycological response). Started Sep 2004; status: completed.
02
Drugs
micafungin
03
Conditions
invasive candidiasiscandidemia
Beyond the preview
Go deeper on NCT00105144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00105144.